



SUVEN Life Sciences

Communication to investors

Mar 2014

22-May-14

2013-14 Q4 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 4 – Mar 2014



• Growth in revenue	75.43%
• Growth in PAT	275.48%
• Growth in EBIDTA	244.11%
• Growth in Pre-R&D EBIDTA	154.72%
• Increase in R&D costs	26.06%
• R&D cost on revenue	9.38%

FINANCIAL QUICK VIEW

Year ending – Mar 2014



- Growth in revenue 98.26%
- Growth in PAT 367.44%
- Growth in EBIDTA 309.54%
- Growth in Pre-R&D EBIDTA 203.68%
- Increase in R&D costs 38.21%
- R&D cost on revenue 9.34%


MAJOR PROFITABILITY RATIOS



	Q4 Mar 14	YE Mar 14
PAT to Income	24.55%	28.08%
EBIDTA to Income	36.85%	43.26%
Cash Flow to Income	26.27%	29.80%
Pre-R&D EBITDA to Income	46.23%	52.60%



INCOME COMPARISON




22-May-14

2013-14 Q4 results



PROFIT COMPARISON




22-May-14

2013-14 Q4 results




EBIDTA COMPARISON



22-May-14


2013-14 Q4 results

R & D – EXPENDITURE





PRE-R&D EBIDTA




22-May-14

2013-14 Q4 results



PRE-R&D CASHFLOW



22-May-14

2013-14 Q4 results



Updates for the quarter

- Suven Life Sciences drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators.
- SUVN D-4010 and SUVN G-3031 are undergoing IND enabling toxicological studies in USA in preparation for Phase 1 clinical trial.
- SUVN-502 undergoing phase 1b clinical trial in USA in preparation for Phase 2a (POC) study on patients in USA
- The Board has proposed a Dividend of Re. 0.50 per share (50% of face value Rs. 1.00 each), with an additional Special Silver Jubilee year dividend of Rs. 2.00 per share (200% of face value of Rs. 1.00 each), aggregating to Rs 2.50 per share for the financial year 2013-14, subject to approval of the shareholders in the ensuing Annual General Meeting.